Trial Nation

Looking for the right place in Europe for clinical trials? 🧬 Did you know that Denmark has the highest number of industry-funded clinical trials per capita across the Organisation for Economic Co-operation and Development (OECD) and Europe’s fastest-growing life science industry? Despite being a small country, Denmark offers a unique clinical trial infrastructure that US companies can benefit from. This week, Invest in Denmark, co-hosted by Innovation Centre Denmark Boston, organized a Clinical Trials Roundtable in Boston, bringing together key players from both the US and Denmark. We were thrilled to have Kristoffer Rohrberg as a guest, a Danish expert in first-in-human oncology trials, who shared insights on Denmark’s innovative capabilities within this field. The roundtable focused on discussing how Trial Nation, which provides a single-entry point for clinical trials in Denmark, and US companies can collaborate and utilize Denmark’s clinical trial ecosystem. If you want to learn more about why a growing number of the world’s major life science companies choose to conduct clinical trials in Denmark, don’t hesitate to reach out to our life science experts, Christian Malherbe and Therese Eilertsen. #ClinicalTrials #LifeScience #Denmark #USCollaboration #Healthcare #Oncology Invest in Denmark | Innovation Centre Denmark Boston | Christian Malherbe | Therese Eilertsen | Thomas Jørgensen | Jens Birk 

94% mener at klinisk forskning er vigtig for udviklingen af nye behandlinger og lægemidler En ny meningsmåling udarbejdet af Norstat på vegne af Trial Nation, Danske Patienter og Organisationen af Lægevidenskabelige Selskaber (LVS) viser en tydelig holdning blandt danskerne: Klinisk forskning er afgørende for udviklingen af nye behandlinger og lægemidler. 1.000 danskere blev spurgt, og svaret er klart – klinisk forskning er vigtig for fremtidens sundhedsbehandlinger. Dette stemmer godt overens med anbefalingerne til den kommende life science-strategi, som fremhæver, at Danmark skal prioritere og udføre mere klinisk forskning som en integreret del af patientbehandlingen. I kronikken, "Sundhedsaktører: Vi skal inddrage klinisk forskning i diskussionen af fremtidens sundhedsvæsen," har flere offentlige og private sundhedsaktører understreget de mange fordele ved sundhedsforskning. Kronikken, der blev publiceret før sommerferien i Altinget.dk, kan godt tåle at blive genopfrisket, mens vi venter på resultaterne af forhandlingerne om Sundhedsstrukturkommissionens anbefalinger og den kommende life science-strategi: ”Når politikerne tegner nye streger for det danske sundhedsvæsen, er der uden tvivl brug for at gentænke indretningen af sundhedsvæsenet i en tid, hvor alle efterspørger ressourcer i form af både finansiering og arbejdskraft. I denne situation er det afgørende, at de politiske beslutningstagere ikke glemmer klinisk forskning. Tværtimod bør den kliniske forskning tænkes mere ind i både den måde, vi organiserer sundhedsvæsenet på, og i den daglige drift af fremtidens sundhedsvæsen. Dermed understøtter vi de mange fordele, som den kliniske forskning giver – ikke mindst for morgendagens patienter, der stadig har brug for at få tilbudt den bedste behandling.” Læs kronikken i sin fulde længde her: https://lnkd.in/dq2C3kgX Morten Freil Anders Perner Marianne Pilgaard Susanne Axelsen *Meningsmålingen blev foretaget blandt 1000 danskere, af Norstat i uge 35, med bred geografisk og aldersmæssig spredning (over 18 år). 35% af de adspurgte fandt at klinisk forskning er vigtig for udviklingen af nye behandlinger og lægemidler, og 59% fandt det meget vigtigt.

Kursus for projektpersonale er i fuld gang! 40 deltagere er samlet til spændende oplæg og netværk på kursus for projektpersonale. På de to dage som kurset varer, vil deltagerne høre om hvordan man opstarter, arbejder med og afslutter kliniske forsøg. Her hører de blandt andet om budgetforhandlinger, GCP og kontrakter i kliniske forsøg.    Der er også tid til gruppediskussioner, hvor deltagerne har mulighed for at diskutere dilemmaer om klinisk forskning med hinanden på tværs af specialer og regioner.  Kurset giver mulighed for at dele viden og erfaringer på tværs af både specialer, regioner og sygehuse. Det synes vi, giver værdi til den kliniske forskning i Danmark. Louise Hansen Karen Bregnehøj Bechgaard Susan Olaf Lindvig Charlotte Calov Pernille Skovby

🌍🌍 𝐉𝐨𝐢𝐧 𝐔𝐬 𝐚𝐭 𝐭𝐡𝐞 8𝐭𝐡 𝐍𝐨𝐫𝐝𝐢𝐜-𝐁𝐚𝐥𝐭𝐢𝐜 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞! The 8th Nordic-Baltic Clinical Trials Conference is taking place on October 30-31, 2024, in Helsinki. This event brings together key stakeholders from the clinical trials community to discuss how we can enhance clinical research in the Nordic and Baltic regions – and Kirsten Bødker, Head of Business Relations at Trial Nation will be there to share a Danish perspective on the topic. The Nordics have long been recognised for our robust healthcare systems and innovative research capabilities. Organisations like Trial Nation, NorTrials and Kliniska Studier Sverige play crucial roles in promoting collaboration across borders, fostering an environment where clinical trials can thrive. What can you expect at the conference? • Insights on the latest EU initiatives aimed at boosting clinical trial competitiveness, such as ACT EU and cross border clinical trials. • Discussions on decentralized clinical trials and harmonizing ethics across countries. • Presentation on national strategies from Finland, Denmark, Norway, and Sweden, showcasing best practices and collaboration opportunities in the clinical trial setting. • Panel discussions on how to translate national initiatives into impactful Nordic strategies. Whether you are a researcher, a healthcare professional, or a policymaker, this conference is a great opportunity to connect and collaborate on clinical trials in our region. Link to more information about the conference here: https://lnkd.in/dzeuFQ3w  

𝐃𝐞𝐜𝐞𝐧𝐭𝐫𝐚𝐥𝐢𝐬𝐞𝐝 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬: 𝐖𝐡𝐞𝐧 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐌𝐞𝐞𝐭𝐬 𝐄𝐯𝐞𝐫𝐲𝐝𝐚𝐲 𝐋𝐢𝐯𝐞𝐬 A recent opinion poll from 1,000 Danes shows that 63% are willing to participate in clinical trials that take place entirely or partially at home or in their local area, utilising digital technology. This reflects a significant openness to trials that bring research closer to the individual citizen. Decentralised clinical trials offer great value to participants who are eager to participate in a trial but may not have the time, ability, or desire to frequently visit hospital departments. These trials leverage digital solutions, bringing healthcare services closer to participants’ daily lives. For example, when medication can be delivered directly to their homes or picked up at a local pharmacy, and consultations are held online or at the local general practitioner, participation becomes easier and more flexible for the individual. It’s all about offering choice and flexible solutions that allow participants to take an active part in research. At Trial Nation, we work to establish solid framework conditions for decentralised clinical trials in Denmark. We do this because decentralised trial designs can help create a more equal access to health research in the Danish population and to support that we have access to the latest treatments now and in the future. Through the PACT** project and collaboration with both public and private partners, we are strengthening the infrastructure so that more trials can be designed with participants and their everyday lives in focus. Read more about the PACT project here: https://lnkd.in/d3iRn42C *The opinion poll was conducted among 1,000 Danes during week 35 by Norstat on behalf of Danish Patients, the Medical Societies, and Trial Nation. 63% of respondents said they are willing to participate in clinical trials that take place entirely or partially at home or in their local area, utilising digital technology. **The PACT-project is funded by Innovationsfonden. The PACT-projects partners are stakeholders from both public and private organisations: Trial Nation, Region Hovedstaden, Region Nordjylland, Region Midtjylland, Region Sjælland, Region Syddanmark, Aalborg Universitet, IQVIA Solutions Denmark A/S, Novartis Danmark, Oticon, World Courier – Specialty Logistics specialist, Merck, Roche and Novo Nordisk.

Yesterday, we had the pleasure of hosting a study visit from representatives of the project group in the preliminary study "Strengthened Competitiveness in Clinical Trials". Sweden is looking at finetuning their capacity building within clinical trials, and the visit provided a great opportunity to share experiences across borders. We discussed successful public-private collaborations in life science, the strengthening of capacities in clinical environments, and the national frameworks that support clinical trials. A big thank you for making the meeting both inspiring and insightful: Kristina Kannisto Jenny Söderberg Maja Neiman Helena Carrick Jenny Almkvist, PhD Frida Lundmark Martina Kvist Reimer Amanda Gyllenswärd Ann Tronde Gunilla Andrew-Nielsen Peter Asplund Monica Lidberg

𝐃𝐞𝐜𝐞𝐧𝐭𝐫𝐚𝐥𝐞 𝐤𝐥𝐢𝐧𝐢𝐬𝐤𝐞 𝐟𝐨𝐫𝐬ø𝐠: 𝐍å𝐫 𝐟𝐨𝐫𝐬𝐤𝐧𝐢𝐧𝐠 𝐦ø𝐝𝐞𝐫 𝐛𝐨𝐫𝐠𝐞𝐫𝐧𝐞𝐬 𝐡𝐯𝐞𝐫𝐝𝐚𝐠 En ny meningsmåling blandt 1000 danskere viser, at 63% gerne vil deltage i kliniske forsøg, der helt eller delvist finder sted i hjemmet eller nærområdet, og hvor der anvendes digital teknologi. Dette vidner om en stor åbenhed over for forsøg, der bringer forskning tættere på den enkelte borger. Decentrale kliniske forsøg kan skabe stor værdi for borgere, der gerne vil deltage i forsøg, men som ikke har mulighed, tid eller lyst til at møde ind på hospitalsafdelingerne ofte. Det er kliniske forsøg, der benytter digitale løsninger og rykker sundhedsydelser tættere på forsøgsdeltagernes hverdag. Når f.eks. medicinen kan sendes direkte hjem eller hentes på det lokale apotek, og konsultationer kan klares online eller hos den lokale praktiserende læge, kan deltagelsen blive lettere og mere fleksibel for den individuelle forsøgsdeltager. Det handler om at give plads til valg og fleksible løsninger. Løsninger der giver deltagerne mulighed for at tage aktivt del i forskningen, uden at det kræver unødvendige ture til hospitalet.  Hos Trial Nation arbejder vi for at decentrale kliniske forsøg bliver etableret i Danmark. Det gør vi fordi det decentrale forsøgsdesign kan bidrage til at skabe mere lighed i sundhed og understøtte at danskerne har adgang til den nyeste behandling nu og i fremtiden. Gennem PACT**-projektet og samarbejdet med både offentlige og private partnere styrker vi infrastrukturen, så flere forsøg kan designes med deltagerne og deres hverdag i fokus. Læs mere om PACT-projektet her: https://lnkd.in/dz6QGEhb *Meningsmålingen blev foretaget i blandt 1000 danskere i uge 35, af Norstat på vegne af Danske Patienter, Lægevidenskabelige selskaber og Trial Nation. 35% af de adspurgte fandt at klinisk forskning er vigtig for udviklingen af nye behandlinger og lægemidler, og 59% fandt det meget vigtigt.  **PACT-projektet er støttet af Innovationsfonden. PACT-projektets partnere er aktører fra offentlige og private organisationer: Trial Nation, Region Hovedstaden, Region Sjælland, Region Syddanmark, Region Midtjylland, Region Nordjylland, IQVIA Nordics, Merck, Novartis Danmark, Novo Nordisk, Oticon, Roche Danmark, World Courier and Aalborg Universitet. 

Insightful discussions at yesterday's CRO- and member meeting! Yesterday, we had a productive and informative meeting with our CRO-network and private membership companies. Diving deep into key aspects of using in-vitro diagnostics in clinical trials, we had the opportunity to share experiences and co-create operational solutions. 𝐈𝐧-𝐕𝐢𝐭𝐫𝐨 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐓𝐞𝐬𝐭𝐬 & 𝐃𝐨𝐜𝐮𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐑𝐞𝐪𝐮𝐢𝐫𝐞𝐦𝐞𝐧𝐭𝐬: We kicked off the meeting with an insightful presentation on the latest documentation and requirements related to in-vitro diagnostic tests in clinical trials. Many thanks to Birgitte Rix Nørgaard from Aarhus University Hospital, Zandra Engelbak Nielsen at Rigshospitalet and the Lægemiddelstyrelsen (Danish Medicines Agency) represented by Kristin Jøranli Astrup, Päivi Susanna Worsøe and Morten Sichlau Bruun, for sharing their expertise and fostering a great dialogue. 𝐍𝐞𝐭𝐰𝐨𝐫𝐤𝐢𝐧𝐠 & 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐓𝐫𝐢𝐚𝐥 𝐍𝐚𝐭𝐢𝐨𝐧 𝐌𝐞𝐦𝐛𝐞𝐫𝐬: During the afternoon session, we welcomed Nicklas Kronvald Jørgensen from the Danish Ministry of Industry, Business, and Financial Affairs, who provided insights into Denmark's efforts to strengthen the life science sector. A big thank you to our private membership companies for joining and contributing to the discussion. These meetings are essential in shaping the future of clinical trials in Denmark, and we look forward to continuing these important conversations!

84% of people would like to be offered the chance to participate in a relevant clinical trials if they are undergoing treatment for a disease. 1,000 Danes were asked about this in an opinion poll conducted by Norstat on behalf of Danish Patients, the Organization of Danish Medical Societies, and Trial Nation. In Denmark, there is a high level of trust in healthcare professionals and the opinion poll highlights the strong interest among the Danish population to participate in clinical research. Testing treatments and new medicines benefits future patients, and in some cases, participation in clinical research can also provide advantages for the individual trial participant. At Trial Nation, we are dedicated to advancing clinical trials in Denmark, ensuring better treatments for patients. *The survey was conducted among 1,000 Danes by Norstat in week 35, with a wide geographical and age distribution (over 18 years old). 52% of the respondents agreed with the statement: "If I am undergoing treatment for a disease, I would like to be offered participation in relevant clinical trials and studies," and 32% strongly agreed with the statement. Danske Patienter Organisationen af Lægevidenskabelige Selskaber (LVS)

Visit from Takeda at Trial Nation Today we had the pleasure of welcoming, together with the Danish affiliate of Takeda, members of the Takeda Global Clinical Research Leadership team for an engaging conversation about Trial Nation and the role of clinical trials in Denmark. It was an insightful exchange where we discussed how clinical research is valued in Denmark and how our public-private partnership model strengthens the clinical trial landscape. By working closely with both public and private stakeholders, we have unique possibilities for conducting clinical trials in Denmark. Thank you for the engaging conversation and insightful questions! We look forward to continuing this dialogue and building strong partnerships to advance clinical trials for the benefit of patients.